Vistagen Therapeutics (VTGN) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research cut shares of Vistagen Therapeutics (NASDAQ:VTGN) from a buy rating to a hold rating in a report issued on Thursday.

According to Zacks, “VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company’s lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. “

A number of other brokerages have also recently weighed in on VTGN. Maxim Group set a $6.00 price target on shares of Vistagen Therapeutics and gave the company a buy rating in a research report on Wednesday, October 3rd. Oppenheimer set a $6.00 price target on shares of Vistagen Therapeutics and gave the company a buy rating in a research report on Tuesday, September 4th. Finally, Chardan Capital reissued a buy rating and issued a $22.00 price target on shares of Vistagen Therapeutics in a research report on Friday, June 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $8.30.

VTGN traded up $0.08 on Thursday, reaching $2.12. The company had a trading volume of 476,700 shares, compared to its average volume of 712,920. Vistagen Therapeutics has a 1 year low of $0.69 and a 1 year high of $2.65. The stock has a market cap of $56.28 million, a PE ratio of -1.91 and a beta of 0.45.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). On average, analysts anticipate that Vistagen Therapeutics will post -0.75 earnings per share for the current fiscal year.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Recommended Story: What does earnings per share mean?

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply